A hybrid photocatalyst with high photocatalytic activity under visible light was developed. The photocatalystgraphene oxide (GO)/hemin/ titanium dioxide (TiO 2) nanocomposite was prepared by a simple method via adsorption at room temperature within 3 h, and was characterised using scanning electron microscopy, X-ray diffraction, X-ray photoelectron spectroscopy and UV-Vis spectroscopy. The results show that TiO 2 nanoparticles were dispersed on the surface of GO sheets uniformly, and the crystal structure remained the same as original anatase TiO 2 phase in the presence of GO and hemin. Extended absorption of the nanocomposite into the visible region is benefit for the novel hybrid photocatalyst to utilise visible light more efficiently in the photocatalytic reaction. The photocatalytic activity increased about 70% in the presence of GO and hemin (96%) comparing to pure TiO 2 (26%). The nanocomposite catalyst could stably adsorb and degrade methylene blue of different concentration without H 2 O 2 or sacrificial electron donor at a relatively wide range of pH values within 3 h. As well as, the prepared GO/hemin/TiO 2 nanocomposite shows good stability and reusability in the photocatalytic reaction, enabling it a potential application in wastewater treatment.
Introduction Increased Mitochondrial (Mito) reactive oxygen species (ROS) generation is a major cause of cardiac ischemia/reperfusion (I/R) injury. p66 Shc is an adaptor protein that regulates multiple pathways governing Mito redox state and ROS generation. Tetrandrine (TET), a bisbenzylisoquinoline alkaloid that is extracted from the root of Stephania tetrandra S. Moore, has been used to treat cardiovascular diseases and hypertension. Here we investigate whether Tet exerts cardioprotection in I/R injury and its underlying mechanism mechanisms. Here we studied the effects of TET on phosphorylation and Mito translocation of p66 Shc, Mito oxidative stress/damage, cardiac function and infarct size in mouse heart model of I/R injury. Methods: Hearts (n = 14 each) isolated from C57BL/6 mice were perfused in the Langendorf mode. After 30‐min equilibration, the heart was treated with TET or vehicle for 10 min, then subjected to global, no‐flow normothermic ischemia for 30 min followed by reperfusion with the corresponding treatment for 120 min. Cardiac function and myocardial energy metabolism were measured with 31 P‐NMR spectroscopy continuously and simultaneously. Effluent was collected to detect the release of lactate dehydrogenase. At the end of the reperfusion, half of the hearts were stained with 2,3,5‐triphenyltetrazolium chloride to evaluate infarct size, whereas the other half were freeze‐clamped and whole protein lysate, cytosolic and Mito fractions were prepared from the clamped tissues to assess the phosphorylation at ser36 and Mito translocation of p66 SHC. Mito H2O2, malondialdehyde (MDA), and protein carbonyls were measured to assess ROS generation and oxidative damage to lipids and proteins, respectively. Results 3 μM TET significantly reduced the heart infarct size and improved cardiac functional recovery after I/R injury. Consistently, TET reversed I/R‐induced increases in H2O2, MDA, and protein carbonyls. Interestingly, 3 μM TET significantly decreased the I/R‐induced phosphorylation of p66 Shc at serine 36 and its translocation to mitochondria. Conclusions: Our data indicate that TET protects the heart against myocardial I/R injury by preventing Mito oxidative damage via mechanisms that are likely to suppressing p66 Shc phosphorylation and Mito accumulation. Targeting p66 Shc phosphorylation and translocation may serve as new therapeutic strategies for I/R injury.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.